UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 4, 2015

 

 

Intersect ENT, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36545   20-0280837

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

  (IRS Employer
Identification No.)

Intersect ENT, Inc.

1555 Adams Drive

Menlo Park, California 94025

(Address of principal executive offices, including zip code)

(650) 641-2100

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 4, 2015, the Company held its Annual Meeting. Proxies for the Annual Meeting were solicited by the Company’s Board of Directors pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended. Of the 23.6 million outstanding shares of the Company’s common stock that could be voted at the Annual Meeting, 16.6 million shares, or approximately 70%, were represented at the Annual Meeting in person or by proxy, which constituted a quorum. The following is a brief description of each matter voted upon at the Annual Meeting, as well as the final tally of the number of votes cast for or withheld with respect to the election of directors, and for or against the ratification of the appointment of Ernst & Young as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2015. A more complete description of each matter is set forth in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 22, 2015.

 

Proposal 1: Each of the seven directors proposed by the Company for re-election was elected by the following votes to serve until the Company’s 2016 Annual Meeting of Stockholders or until his respective successor has been elected and qualified. The tabulation of votes on this matter was as follows:

 

     For    Withheld    Broker
Non-Votes

Kieran T. Gallahue

       13,829,155          4,916          2,734,363  

Lisa D. Earnhardt

       13,812,655          21,416          2,734,363  

Cynthia L. Lucchese

       13,780,401          53,670          2,734,363  

Dana G. Mead, Jr.

       13,812,655          21,416          2,734,363  

Frederic H. Moll, M.D.

       13,377,848          456,223          2,734,363  

Casey M. Tansey

       13,812,655          21,416          2,734,363  

W. Anthony Vernon

       13,780,401          53,670          2,734,363  

 

Proposal 2: The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2015 was ratified. The tabulation of votes on this matter was as follows:

 

For    Against    Abstain    Broker
Non-Votes
16,496,728    71,706      


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Intersect ENT, Inc.
Dated: June 5, 2015
By: /s/ Jeryl L. Hilleman
Jeryl L. Hilleman
Chief Financial Officer